Cell experiments have shown that osimertinib combined with MEK inhibitor selumetinib can delay the emergence of drug resistance, and a phase I trial (NCT03392246) of osimertinib combined with selumetinib in the treatment of EGFR-mutant advanced NSCLC patients is ongoing. Here, EGFR is linked to non-small cell lung carcinoma.